Year: 2019

Scholar Rock Reports Preliminary Pharmacokinetic and Pharmacodynamic Data from TOPAZ Phase 2 Trial of SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy

Written by Customer Service on November 19, 2019. Posted in Public Companies.

Biomarker results confirm presence of latent myostatin in patients with SMA, further supporting relevance of drug target in diseaseSRK-015 demonstrated robust and dose-dependent target engagementData provide first evidence of successful pharmacologic engagement of a latent growth factor in a human disease settingCAMBRIDGE, Mass., Nov. 19, 2019 (GLOBE NEWSWIRE) — Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced preliminary pharmacokinetic (PK) and pharmacodynamic (PD) results from the TOPAZ Phase 2 proof-of-concept trial of SRK-015 for the treatment of patients with spinal muscular atrophy (SMA). The planned preliminary PK/PD analysis, which includes data from 29 patients with SMA across all...

Laurentian Bank Financial Group declares dividends on its preferred shares

Written by Customer Service on November 19, 2019. Posted in Public Companies.

MONTREAL, Nov. 19, 2019 (GLOBE NEWSWIRE) — Laurentian Bank of Canada (TSX: LB) (the “Bank”) announces that its Board of Directors declared today the following dividends:a dividend of $0.2576875 on the preferred shares Series 13, payable on December 15, 2019, to shareholders of record at the close of business on December 6, 2019.a dividend of $0.365625 on the preferred shares Series 15, payable on December 15, 2019, to shareholders of record at the close of business on December 6, 2019.The above-mentioned dividends are designated as eligible dividends for the purposes of the Income Tax Act (Canada) and any similar provincial and territorial legislation.The preferred shares are Eligible Shares under the Bank’s Shareholder Dividend Reinvestment and Share Purchase Plan (the “Plan”). Consequently, the holders of such shares...

Formula Systems Reports Third Quarter 2019 Results

Written by Customer Service on November 19, 2019. Posted in Earnings Releases And Operating Results.

OR YEHUDA, Israel, Nov. 19, 2019 (GLOBE NEWSWIRE) — Formula Systems (1985) Ltd. (NASDAQ: FORTY), a global information technology holding company engaged, through its subsidiaries and affiliates, in providing software consulting services and computer-based business solutions and developing proprietary software products, today announced its results for the nine month-period and third quarter ended September 30, 2019.Financial Highlights for the Third Quarter Ended September 30, 2019Consolidated revenues for the third quarter increased by 23.9% to $449.0 million, with growth recorded across Formula’s entire investment portfolio. Revenues for the third quarter ended September 30, 2018 amounted to $362.4 million.Consolidated operating income for the third quarter increased by 39.4% to $37.0 million, with growth recorded across Formula’s...

Gilat Reports Strong Growth in Q3 2019

Written by Customer Service on November 19, 2019. Posted in Earnings Releases And Operating Results.

GAAP Operating Income Increases 43.1% sequentially; Adjusted EBITDA reaches double digits totaling $10.1 millionGilat wins coveted deal for SES O3b mPOWER MEO Communications SystemPETAH TIKVA, Israel, Nov. 19, 2019 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today reported its results for the third quarter ended September 30, 2019.Key Financial Highlights:Revenues for Q3 2019 increased to $63.4 million compared with $59.7 million for Q2 2019 and $62.8 million in Q3 2018.Continued strong profitability:° Q3 2019 GAAP operating income increased 17.1% to $7.0 million from $6.0 million in Q3 2018 and was up 43.1% from $4.9 million in Q2 2019. Non-GAAP operating income in Q3 2019 rose to $7.5 million, or by 15.4% from Q3 2018 and...

Helius Medical Technologies, Inc. Announces Addition of P3 Health As New Authorized PoNS Treatment™ Clinic in Toronto, Canada

Written by Customer Service on November 19, 2019. Posted in Public Companies.

NEWTOWN, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported that a new location has been authorized to become a PoNS Treatment™ Center in Canada bringing broader regional access to its innovative PoNS Treatment in the Toronto area. P3 Health is a leading healthcare facility located in downtown Toronto’s St. Lawrence Market area at 145 Front Street East Suite G2 Toronto, Ontario Canada M5A 1E3.“The PoNS™ gives us an opportunity to manage a vital area of neurorehabilitation with more precision than ever before. We’re extremely excited to integrate it into our clinic,” said Elliot Jacobson, MD CCFP (EM) ABIHM.Since the opening of the first certified clinic, Neurotherapy Montreal, in December...

Formula Systems Acquires Unique Software Industries Ltd. for Approximately NIS 61 Million

Written by Customer Service on November 19, 2019. Posted in Mergers And Acquisitions.

The acquisition enables the Group to expand its operations in the field of management of payroll and human resources, in which it currently operates through its subsidiary, MichpalOr Yehuda, Israel, Nov. 19, 2019 (GLOBE NEWSWIRE) — Formula Systems (1985) Ltd. (NASDAQ and TASE: FORTY) announced today that it had completed its acquisition of 100% of the outstanding shares of Unique Software Industries (“Unique”) for consideration consisting of NIS 49 million in cash, plus up to NIS 12 million of additional cash that may be paid during the four years following the closing of the acquisition, subject to Unique’s achievement of certain performance goals as defined by Formula.Unique is a software development and services company, which during its 30 years of operations, has provided integrated solutions in the field of payroll, including...

RedHill Biopharma Reports Third Quarter 2019 Financial Results and Operational Highlights

Written by Customer Service on November 19, 2019. Posted in Earnings Releases And Operating Results.

Key Highlights:U.S. FDA approval of Talicia® for the treatment of Helicobacter pylori infection in adults Strategic partnership with Cosmo Pharmaceuticals, including investment of $36.3 million and exclusive rights to commercialize Aemcolo®in the U.S. for travelers’ diarrhea Accelerating expansion of commercial sales team in the U.S. ahead of planned launches of Aemcolo® and Talicia® in Q4/2019 and Q1/2020, respectively Debt-free balance sheet with approximately $59 million as of October 22, 2019 following the investment by Cosmo Pharmaceuticals Hosting an investor and analyst event in New York on November 22, 2019, to discuss planned U.S. commercial launches of Talicia® and Aemcolo® Management to host a conference call today at 8:30 a.m. EST to review the third quarter financial results and operational highlightsTEL-AVIV, Israel and...

XPO Logistics Expands Use of Intelligent Robotics in the UK Ahead of Holiday Shopping Season

Written by Customer Service on November 19, 2019. Posted in Public Companies.

GREENWICH, Conn, Nov. 19, 2019 (GLOBE NEWSWIRE) — XPO Logistics (NYSE: XPO), the largest outsourced e-commerce fulfillment provider in Europe, has increased its use of intelligent robotics in the UK in anticipation of holiday retail volumes. The robots work alongside XPO’s employees to help manage inventory for distribution during the seasonal peak. The automation is manufactured by 6 River Systems, Inc., part of leading global commerce company Shopify and one of XPO’s key robotics partners in the US.The autonomous, mobile robots collaborate with employees and adapt quickly to changes in fulfillment. The robots guide employees to the correct inventory area, validate the items picked and transport them to designated packing stations. The technology uses machine learning to double productivity rates on average and improve accuracy...

Trigon Enters Into Agreement to Acquire the High Potential ‘Silver Hill’ Copper and Silver Project in Morocco

Written by Customer Service on November 19, 2019. Posted in Public Companies.

TORONTO, Nov. 19, 2019 (GLOBE NEWSWIRE) — Trigon Metals Inc. (TSX-V: TM) (“Trigon” or the “Company”) is pleased to announce that it has entered into a non-binding Memorandum of Understanding (“MOU”) to acquire a 100% interest in the Silver Hill Project (“Silver Hill” or the “Project”) in Morocco (the “Proposed Transaction”).The Proposed Transaction is centered around the Silver Hill Project, a 16km2 property in the Anti-Atlas region of Morocco, already home to Africa’s major silver mines (Imiter, Zgounder). Morocco is well-known to be a favourable jurisdiction for mining, with an established industry producing at a rate of approximately 40 million tonnes of minerals per year. Morocco produces 90% of the world’s supply of phosphates, and extracts copper, cobalt, gold silver and zinc. Morocco is a friendly business environment with...

REMINDER: Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

Written by Customer Service on November 19, 2019. Posted in Public Companies.

EWING, N.J., Nov. 19, 2019 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) today announced that it has entered into a global agreement with Idorsia Pharmaceuticals Ltd. (“Idorsia”) (SIX: IDIA) to develop a novel, drug-device product combining selatogrel, Idorsia’s potent, fast-acting and highly selective P2Y12 receptor antagonist under development, with the Antares subcutaneous QuickShot® auto injector. Selatogrel, a new chemical entity (NCE), is being developed for the treatment of a suspected acute myocardial infarction (AMI) in adult patients with a history of AMI. Idorsia’s Phase 2 clinical data demonstrated that subcutaneous administration of selatogrel resulted in a potent and rapid platelet inhibition effect in patients with a history of coronary artery disease and AMI. According to Idorsia, the product...

Year: 2019

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals